
Opinion|Videos|September 20, 2024
Future Direction of Intravenous and Subcutaneous Biologics
Author(s)Jennifer Seminerio, MD
Dr. Seminerio predicts how the future landscape will change for intravenous and subcutaneous biologics.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Do you foresee IV and subQ route of administration always having a role moving forward? How do you see the treatment landscape changing?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves Lipfendra, first oral PCSK9 inhibitor
2
How the most favored nation drug pricing policy is quietly reshaping drug development and clinical research
3
Capital Rx is now Judi Rx in a company rebrand
4
FTC secures settlement with Caremark, locks in up to $8.5 billion in consumer savings
5

























